Biorthex Anticipating Fourth-Quarter Roll-Out Of SpineCor Scoliosis Brace
This article was originally published in The Gray Sheet
Executive Summary
Biorthex is planning a fourth-quarter U.S. launch of its SpineCor scoliosis brace, pending 510(k) clearance by FDA. Priced at approximately $1,000, the device will be positioned as an alternative and less restrictive treatment for early idiopathic scoliosis.
You may also be interested in...
Degenerative Disc R&D Heats Up: Biorthex Evaluates Cervical Fusion Device
Biorthex' recent IDE for the Actipore ACF places the Montreal-based firm with Medtronic and Synthes-Stratec in developing cervical implant approvals for the U.S. market
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.